LY-293,284

LY-293,284 is a research chemical developed by the pharmaceutical company Eli Lilly and used for scientific studies. It acts as a potent and selective 5-HT1A receptor full agonist. It was derived through structural simplification of the ergoline based hallucinogen LSD, but is far more selective for 5-HT1A with over 1000x selectivity over other serotonin receptor subtypes and other targets. It has anxiogenic effects in animal studies.